KVH Industries Reports Third Quarter 2025 Results GlobeNewswire November 06, 2025 MIDDLETOWN, R.I., Nov. 06, 2025 (GLOBE NEWSWIRE) — KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended September 30, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed […]

Datadog Announces Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 Third quarter revenue grew 28% year-over-year to $886 million Robust growth of larger customers, with about 4,060 $100k+ ARR customers, up from about 3,490 a year ago Reached a milestone of over 1,000 integrations on the Datadog unified platform NEW YORK, Nov. 06, 2025

Playboy and Hefner Capital Announce Creative Partnership to Produce Feature Film DEAD AFTER DARK GlobeNewswire November 06, 2025 LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — Playboy, Inc. (NASDAQ: PLBY) (the “Company” or “Playboy”) and Hefner Capital today announced a new creative partnership to produce Dead After Dark, an original feature film currently in development.

Apyx Medical Corporation Reports Third Quarter 2025 Financial Results GlobeNewswire November 06, 2025 Initiated full U.S. commercial launch of AYON Body Contouring System(TM) (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectations Submitted new 510(k) for AYON for device label expansion to include power liposuction Increased total revenue guidance for FY2025 to

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma GlobeNewswire November 06, 2025 NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A.

Baker Hughes Secures Additional Order for Rio Grande LNG Expansion GlobeNewswire November 06, 2025 Award from Bechtel includes supply of the primary liquefaction equipment for NextDecade's Rio Grande LNG Train 5 Order includes Frame 7 gas turbines and centrifugal compressors, replicating proven solutions from previous trains Technology will enable an additional LNG production capacity of

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire November 06, 2025 Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership team with key appointments in business development and human resources Cash

FactSet Declares Dividend GlobeNewswire November 06, 2025 NORWALK, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced that its Board of Directors approved a regular quarterly cash dividend of $1.10 per share. The cash dividend will be paid on December

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 06, 2025 Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care Mind Medicine Australia clinic joins Psyence BioMed's expanding network of clinical sites as enrollment accelerates in the landmark Phase IIb study for Adjustment Disorder in palliative care GlobeNewswire November 06, 2025 NEW YORK, Nov. 06, 2025